Robert J Adelman
CIK 1329161 · last filed 2023-09-21
Robert J Adelman is a corporate insider who has filed 11 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for RYZB, was dated Sep 21, 2023. Across all open-market trades the lifetime net is −$41.0M, making them a net seller over the disclosed history. 39 SEC filings were submitted jointly with COREY S GOODMAN.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
5
11
-$41.03M
Filer Profile
SUITE 595
SAN FRANCISCO, CA 94158
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RayzeBio, Inc. (RYZB) Delisted | 10%+ Owner | 4,910,819 | $62.49 | $306.88M | $0 | 1 | 2023-09-21 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | 10%+ Owner | 2,155,930 | $10.50 | $22.64M | -$6.88M | 1 | 2022-05-17 |
| Metacrine, Inc. (MTCR) Delisted | Director | 2,443,421 | $0.49 | $1.21M | -$1.65M | 2 | 2021-10-26 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 3,033,552 | $54.65 | $165.78M | -$35.50M | 4 | 2020-07-06 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | Director | 3,340,139 | — | — | $3.00M | 3 | 2008-11-18 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-09-21 | RayzeBio, Inc. (RYZB) Delisted | Conv (C) | +25,790,810 | $0 | EDGAR |
| 2022-05-17 | Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | Sell (S) | −658,250 | -$6.88M | EDGAR |
| 2021-10-26 | Metacrine, Inc. (MTCR) Delisted | Sell (S) | −3,078,510 | -$4.64M | EDGAR |
| 2020-09-22 | Metacrine, Inc. (MTCR) Delisted | Mixed | +3,059,123 | $2.99M | EDGAR |
| 2020-07-06 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −582,335 | -$20.03M | EDGAR |
| 2020-02-12 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −50,130 | -$1.36M | EDGAR |
| 2020-02-06 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −411,695 | -$10.61M | EDGAR |
| 2020-01-06 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −177,490 | -$3.50M | EDGAR |
| 2008-11-18 | ARYx Therapeutics, Inc. (ARYX) Delisted | Buy (P) | +1,214,646 | $0 | EDGAR |
| 2007-11-14 | ARYx Therapeutics, Inc. (ARYX) Delisted | Mixed | +2,125,493 | $3.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.